Resistencias a antibióticos

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

Duración
01/03/2015 - 28/02/2020
Coordinador
Jordi Vila
Financiadores
Innovative Medicines Iniciatives 2 (IMI-2)

Infections caused by bacteria known as ‘carbapenem-resistant enterobacteriaceae’ (CRE) are resistant to most available antibiotics and are so difficult to treat they are considered to be one of the most dangerous drug-resistant bacteria in the world. Worryingly, cases of CRE infections are on the rise in Europe and globally.

The COMBACTE-CARE project aims to shed new light on the best ways to understand and treat CRE infections. It will also run clinical trials of a novel antibiotic combination product designed to tackle a sub-type of CRE infections for which there are limited or no treatment options.

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

VINCI

Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique